Actinium Pharmaceuticals, Inc. — FY 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. This is an annual report, not a standalone fourth-quarter report. Actinium is a clinical-stage oncology company with no commercial sales; its lead programs use radioisotopes attached to antibodies.
Financial results and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $17.5 million | $13.3 million |
| General and administrative expense | $9.3 million | $11.5 million |
| Operating loss | $26.8 million | $24.8 million |
| Net loss | $24.3 million | $21.0 million |
| Net loss per share, basic and diluted | $0.50 | $0.55 |
| Cash used in operating activities | $20.8 million | $18.5 million |
| Cash and cash equivalents, year-end | $20.5 million | $25.6 million |
- R&D rose about $4.2 million, principally from increased Actimab-A costs and research staff compensation. G&A fell about $2.2 million, largely due to lower stock-based compensation and professional fees.
- The net loss widened by about $3.3 million despite lower G&A, partly because the noncash gain from revaluing derivative warrant liabilities declined to $2.5 million from $3.8 million.
- Year-end total assets were $22.5 million, total liabilities $4.5 million and stockholders’ equity $18.0 million. Notes payable were zero; liabilities included $0.3 million of derivative liabilities and $4.2 million of accounts payable and accrued expenses. No profitability or meaningful operating margin was reported.
- Financing activities provided $15.8 million in 2016, including approximately $16.0 million net proceeds from stock sales. Shares outstanding increased from 44.1 million at year-end 2015 to 55.8 million at year-end 2016, reflecting dilution.
Business progress and changes from the prior year
- Iomab-B: The FDA-cleared pivotal Phase 3 trial began in 2016. The randomized, controlled study is planned for 150 patients aged 55 or older with relapsed or refractory AML undergoing stem-cell transplantation. Durable complete remission is the primary endpoint; one-year overall survival is secondary. Management estimated direct trial-completion costs of approximately $25 million and anticipated completion in 2018, subject to trial progress.
- Actimab-A: The company began a 53-patient Phase 2 study in September 2016 for newly diagnosed AML patients aged 60 or older. It is evaluating the drug as monotherapy, with protocol changes including peripheral-blast criteria and mandated supportive treatments. Management expected an interim analysis in mid-2017 and topline results in the second half of 2017.
- Actimab-A Phase 1 results reported in the filing included objective responses in 5 of 18 patients and a median response duration of 9.1 months; these early results do not establish later-stage efficacy or approval.
- R&D expense and operating cash use increased as the company advanced its clinical trials. The company also reported an increase in its workforce and clinical-trial spending.
Outlook, risks and notable items
- Management stated that year-end cash was expected to fund operations for the next 12 months and estimated approximately $14.6 million would be needed over that period for R&D and working capital. The company nevertheless said additional capital would be needed to complete development and commercialization; funding may require dilutive equity or debt, or partnering that gives up rights.
- The company had no product revenue, had accumulated a $136.6 million deficit, and expected continuing losses. It reported no assurance that candidates will succeed in trials, receive regulatory approval, or be commercialized.
- Key risks include clinical-trial safety, enrollment and efficacy; dependence on contract manufacturers and research organizations; reliance on ORNL for Ac-225 supply under a contract expiring at the end of 2017; regulatory, reimbursement and commercialization uncertainty; and financing and dilution risk.
- Intellectual-property protection is uneven: the filing states Iomab-B is not patent-protected as a product, while Actimab-A depends on licensed antibody and platform rights, related royalties and milestones. The company also depends on renewal of isotope-supply arrangements and on developing alternative Ac-225 manufacturing capacity.
- The company reported no material legal proceedings or off-balance-sheet arrangements. Its independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective at year-end.
Important facts for investors to verify
- Current cash, actual operating burn, and whether the stated 12-month funding estimate remains adequate as trial spending advances.
- Enrollment, safety and endpoint progress in the Iomab-B Phase 3 and Actimab-A Phase 2 trials, including whether the stated result timelines were achieved.
- Renewal and adequacy of Ac-225 supply, and practical readiness, cost and access to alternative production capacity.
- Potential dilution from future financings, outstanding options and warrants, and the terms of any partnership or licensing agreements.
- Milestone, royalty and other contractual obligations, including the accrued $750,000 AbbVie Phase 2 milestone and future development commitments.